AAMS Infectious Diseases & Microbiology · Vol. 1 · Issue 4 · 2024-12-12
Tuberculosis Treatment Outcomes with Novel Bedaquiline-Based Regimens: A Phase III Trial
Ndlovu ZM, Mthembu S, Dlamini P
Department of Pulmonology, University of KwaZulu-Natal, Durban, South Africa¹; South African Medical Research Council, Cape Town, South Africa²
Abstract
Phase III randomized trial of 450 patients with drug-resistant tuberculosis demonstrates that bedaquiline-pretomanid-linezolid regimen achieves 90% culture conversion at 6 months with acceptable safety profile.
Keywords: Tuberculosis, Bedaquiline, Drug Resistance, Phase III Trial, Treatment Outcomes
Full Text